



Review

# To a Question on the Mechanism of the Antimicrobial Action of Ortho-Benzoic Sulfinamide

Ekaterina Y. Kasap and Dmitry V. Grishin \*

Institute of Biomedical Chemistry (IBMC), Department of Research Laboratories, 119121 Moscow, Russia; biogene@bk.ru

\* Correspondence: molbiol\_ibm@inbox.ru; Tel.: +7-9689-1298-90

Received: 17 September 2020; Accepted: 11 December 2020; Published: 13 December 2020



**Abstract:** The article summarizes and compares data on the properties and biological activity of *o*-benzoic sulfinamide and sulfanilamide compounds. Attention is given to the biochemical conditions under which *o*-benzoic sulfinamide and sulfanilamides have similar activity groups. The results of the experimental and theoretical studies aimed at understanding the molecular organization and biological activity of folic acid and its homologous complexes are analyzed. A hypothesis about the possible mechanisms of the formation of such complexes with the participation of *o*-benzoic sulfinamide is presented. The perspectives for the use of *o*-benzoic sulfinamide and its homologues in biomedicine are evaluated.

**Keywords:** *o*-benzoic sulfinamide; saccharin; sulfanilamide; folic acid; antimicrobial action


## 1. Introduction

*o*-Benzoic sulfinamide (1,1-dioxo-1,2-benzothiazol-3-one), better known as saccharin (Figure 1), was accidentally discovered by a chemist Constantin Fahlberg in 1879 when studying the oxidation of *o*-toluenesulfonamide for work on coal tar derivatives in the laboratory of Prof. Ira Remsen at Johns Hopkins University [1]. At this point, scientists came to understand that the crystalline hydrate of saccharin is a hundred times as sweet as sucrose (table sugar) and, for this reason, the future of this substance was associated with medicine and dietology [2–5]. A method for manufacturing saccharin was patented in 1884–1885 [6]. Initially, Fahlberg obtained saccharin from toluene by sulfation with sulfurochloridic acid. The resulting acid chloride was converted into an amide that was oxidized with potassium permanganate. Unfortunately, this method was not effective enough. In the 1950s, O. Senn and G. F. Schlaudecker developed an alternative approach that began with methyl anthranilate, which was easily procured from phthalimide or phthalic anhydride (Figure 2). Its diazotization and serial treatment with sulfur dioxide, chlorine, and finally ammonia led directly to saccharin [7].

*o*-Benzoic sulfinamide gained popularity as a sugar substitute for diabetics in the 1960s when the Maumee Chemical Company of Toledo, Ohio, USA adapted Senn and Schlaudecker's method for commercial application, allowing for the production of saccharin on an industrial scale. The major advantage of this new method was the avoidance of the costly separation of ortho- and para-isomers [7].

At the same time, the side effects of this chemical compound began to be discussed. As a result of a number of studies in the 1970s, concern arose over the carcinogenic properties of saccharin [8–12] such that a number of countries restricted its use in the food industry [13]. However, these assumptions were later refuted, since the incidence of bladder cancer in laboratory mice increased only if the amount of saccharin consumed significantly exceeded the acceptable dosage [14–16]. Similar studies found sodium saccharin did not increase the mutant frequency in the liver or bladder of the rats. These results added further support to the existence of a non-genotoxic mechanism of carcinogenic action for sodium saccharin in mice [11]. After subsequent studies failed to confirm a link between

*o*-benzoic sulfimide and bladder cancer in humans, saccharin was removed from the list of potential carcinogens in the year 2000 [17]. The current United States Food and Drug Administration (FDA) confirms the acceptable daily intake (ADI) of 15 milligrams per kilogram body weight per day (mg/kg bw/d) as safe in humans [18–28].



**Figure 1.** Structural and molecular formulas and relative molecular mass of saccharin and its derivatives.

During the same period, studies revealed a relationship between gut microbiome perturbed by saccharin and the expression of pro-inflammatory cytokine-inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF- $\alpha$ ) in the liver [19–28]. Subsequent studies have shown that *o*-benzoic sulfimide and its derivatives in concentrations from 1 to 320 mg/mL may have different inhibitory efficiencies on different bacterial species in vitro and in vivo [20–24,28,29]. For example, it was shown that 5 mmol of saccharin exhibits statistically significant bacteriostatic effects on *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, but results in a complete abrogation of bacterial growth in *Bacillus cereus* [28].

However, despite the importance of this information, the antibacterial properties of saccharin and its homologues have not been closely studied because a mechanism for the action of these compounds on microbial cells has not yet been proposed.

Thus, this article generalizes and compares the data on the structural organization and biological activity of saccharin, searching for the most probable targets for its antimicrobial action and modeling the possible mechanism of such action at the molecular level.


## 2. *o*-Benzoic Sulfimide: Physical and Chemical Properties, Synthesis, and Structural Organization

A better understanding of the molecular mechanism underlying the possible pharmacological effect of *o*-benzoic sulfimide can be found in its physical and chemical properties.

From a physicochemical point of view, saccharin is a colorless to white powder crystallizing in a monoclinic crystal system with a density of  $0.828 \text{ g/cm}^3$  [30–32]. The melting point is usually close to  $228 \text{ }^\circ\text{C}$ , but when in its salt form, the melting point can exceed  $300 \text{ }^\circ\text{C}$  [32,33]. This substance is used industrially both in the form of acid and in the form of salt. The acid form is poorly soluble in water and diethyl ether ( $2 \text{ g/L}$  at  $20 \text{ }^\circ\text{C}$ ) and slightly more soluble in ethanol and acetone [31–33], so industries are more likely to use calcium and sodium salts, which are easily soluble in polar solvents ( $370 \text{ g/L}$  and  $1000 \text{ g/L}$  at  $20 \text{ }^\circ\text{C}$ , respectively) (Figure 1) [32].

From an organoleptic point of view, benzoic sulfimide solutions have a high sugar identity; saccharin, on average, is 300 times sweeter than sucrose [2]. The LD50 for this substance is  $1280 \text{ mg/kg}$  when it is administered orally to rats [34].

From a structural point of view, a molecule of saccharin is a derivative of the isoindole-1,3-dione (phthalimide (I)). For this reason, methods for the synthesis of *o*-benzoic sulfimide are based primarily on the reaction of converting phthalimide to methyl anthranilate (II), followed by its conversion to *o*-benzoic sulfimide (IV) through the formation of an intermediate called methyl 2-(chlorosulfonyl) benzoate (III) by stepwise interaction with nitrous acid, sulfur dioxide, chlorine, and ammonia [30] (Figure 2).



**Figure 2.** A simplified scheme of the sequence of chemical reactions in the conversion of phthalimide (I) to *o*-benzoic sulfimide (IV).

### 3. Mechanism of the Biogenic Transformation of Saccharin


In order to understand the mechanism of the antimicrobial action of saccharin, it is necessary to start with the fact that the cyclic form of *o*-benzoic sulfimide does not have active radicals that could help it quickly engage in crucial metabolic processes in pro- and eukaryotic cells. This leads to the conclusion that the cyclic form of saccharin is probably a prodrug that needs to be bioactivated. The target for such activation can be the substituted isothiazolidine ring, since it is known that substituted thiazolidines have a high hydrolysis lability in contrast to their non-substituted analogues [35,36]. The known data on the enzymatic and chemical modification of imide, lactam, and other similar cycles under extreme pH values can serve as indirect confirmation of the possibility of such a transformation [37–42]. Special attention should also be paid to reports on the use of saccharin as an alternative reagent for Gabriel synthesis (synthesis of primary amines). What is interesting is not so much the reaction itself, but its initial stages, during which, apparently, the alkaline opening of the heterocyclic compound within the structure of saccharin and its closest homologues occurs [43–45].

When entering the cells of pro- and eukaryotes, saccharin may be affected by high pH values and by a whole complex of enzymes, including the cytochrome P450 superfamily (CYPs; EC 1.14.14.1),

which catalyzes the oxidation of the compounds with aliphatic or aromatic rings [45–53]. Given this, it is obvious that the isothiazolidinic ring of *o*-benzoic sulfimide can undergo chemical and/or enzymatic decyclization. The resulting radicals turn *o*-benzoic sulfimide into an activated form (XII) similar in many ways to the derivatives of *p*-amino benzenesulfonamide (sulfanilamides) and with the full range of inherent properties of these compounds. The proposed mechanism of such modification is shown in Figure 5, stage 1.


#### 4. Folic Acid: A Unique Therapeutic Target

While discussing this topic, it is important to remember that in the 1940s, scientists discovered the precursors of a representative group of antimicrobial drugs containing *p*-aminobenzenesulfonamidic pharmacophore that could affect streptococcal bacteria [54,55], the most striking representative of which is red streptocide (Figure 3V). It was later discovered that this substance is not a drug, but rather a prodrug. The active principle was discovered to be its metabolite called sodium, (4-sulfamoylanilino) methanesulfonate (Figure 3VI). This substance is a modified water-soluble form of white streptocide (Figure 3VII), which was later obtained in its pure state [54,56].



**Figure 3.** Structural and molecular formulas of historically first forms of sulfanilamide pharmaceuticals.

The mechanism of the antibacterial action of sulfanilamides was studied in detail in subsequent years. In their development, prokaryotic cells, in contrast to higher eukaryotes, are capable of independent de novo synthesis of folic acid. Folic acid (folate) belongs to the Bc vitamin group that forms the structural basis of the cofactors that are mandatory participants in the transfer and transformation of single-carbon groups in the biosynthesis of nucleic acids and amino acids [57,58]. The structure of normal folate contains a residue of 2-amino-4-hydroxy-6-pyrophosphoryl-methylpteridine (Figure 4, VIII), a residue of L-glutamic acid (glutamate), and a fragment of *p*-aminobenzoic acid (Figure 4, IX) [59]. Since the enzyme that performs folic acid biosynthesis in a microbial cell (dihydropteroate synthase, DHPS) acts non-specifically during such assembly, sulfanilamides enter into intense competition with *p*-aminobenzoic acid for the active center of this enzyme [60–62]. As a result, a mimetic of aminobenzoic acid called sulfanilamide fragment is included in the composition of vitamin Bc instead of natural aminobenzoic acid, which leads to the appearance of pseudofolic acid (Figure 4, XI). This disabled vitamin cannot become a full-fledged metabolite for the biosynthesis of nucleic acids and proteins of the microorganism, which is the basis of the specific bacteriostatic and bactericidal action of sulfanilamides [54,63–66].




**Figure 4.** Simplified scheme of biosynthesis of normal folic acid (X) and pseudofolic acid (XI) (partly adapted from [54]).

## 5. Modeling of the Mechanism of *o*-Benzoic Sulfinamide Antibacterial Action

The theoretical analysis suggests that the antibacterial effect of saccharin is directly related to the isothiazolidine heterocyclic ring that has the ability for biogenic transformation into an activated form in pro- and eukaryotic cells [67–69]. This modification may be due to the chemical and/or enzymatic lability of substituted thiazolidine rings.

When saccharin enters bacterial cells or the human body, it is exposed to extreme pH values [70–72] and the influence of cytochrome P-450 enzymes. These enzymes catalyze the oxidation of compounds with aliphatic or aromatic rings, such as the isothiazolidine ring of *o*-benzoic sulfinamide (IV), which undergo decyclization to form a compound called *o*-sulphamoylbenzoic acid (XII), which is a structural analog of the antibacterial compounds of the sulfonamides class. In other words, saccharin has antibacterial activity only if it is transformed by the enzyme systems of micro- and/or macroorganisms. *o*-sulphamoylbenzoic acid can be absorbed by both symbiotic and pathogenic microflora. It starts to compete with native *p*-aminobenzoic acid in the bacterial cell and is mistakenly included by the bacterial enzyme complexes in the composition of pseudofolic acid (Figure 5, XV), which cannot provide normal biosynthesis of nucleic acids and many bacterial proteins. This process of pseudofolic acid synthesis passes through the interaction of the phosphorylated form of 2-amino-4-hydroxy-6-pyrophosphoryl-methylpteridine and *o*-sulphamoylbenzoic acid (Figure 5, stage 2) with the formation of an intermediate, and then one or more L-glutamic acid molecules are attached to it at the final stage (Figure 5, stage 3).



**Figure 5.** Three hypothetical stages of pseudofolic acid formation based on activated saccharin (IV). Stage (1), formation of *o*-sulphamoylbenzoic acid (XII); stage (2), interaction of 2-amino-4-hydroxy-6-pyrophosphoryl-methylpteridine (VIII) and (XII) with the formation of an intermediate (XIII); stage (3), interaction of (XIII) and L-glutamic acid (XIV) with the formation of a homologue of pseudofolic acid (XV).

## 6. The Problem of Bacterial Resistance to Sulfonamides

Sometimes parallels between the systems of bacterial resistance to antibiotics and sulfonamides are drawn. In our opinion, this is not entirely correct. For example, the most odious enzymes involved in the utilization of beta-lactam antibiotics are plasmid-encoded  $\beta$ -lactamases.

Current phylogenetic analyses have estimated the age of plasmid-encoded  $\beta$ -lactamases appearing millions of years ago [73–75].

A metagenomic DNA study from 30,000-year-old permafrost sediments east of Dawson City, Yukon (Canada) deduced amino acid sequences with up to 84% identities to the modern  $\beta$ -lactamases [75,76]. If we consider the system of resistance to sulfonamides, then only a few studies have shown that some monooxygenases of *Microbacterium* sp. CJ77 cleavage the sulfonamides [77]. The main bacterial resistance to sulfonamides predominantly occurs because of mutations in *folP* gene encoding dihydropteroate synthase (DHPS) involved in nucleotide biosynthesis or through acquisition of alternative DHPS genes (*sul1*, *sul2*, *sul3*, and *sul4*), the products of which may have low affinity to sulfonamides [77].

The *folP* gene is present in the genomes of both bacteria and archaea [78], which indicates that both this gene and the mechanism of folate biosynthesis itself probably originated in the ancestral forms of all prokaryotes, i.e., at least 3 billion years ago.

It is obvious that the DHPS is a representative of a much older, vital, and stable prokaryotic folate biosynthetic pathway, in contrast to the  $\beta$ -lactamases. In particular, for this reason, the folate pathway continues to be a promising target for the development of new drugs for antimicrobial therapy. However, there are a number of side effects that require a more balanced approach in the development of new sulfonamide drugs.

These side effects include a non-specific effect on the normal microflora of the gastrointestinal tract and off-target effects of sulfonamide antibiotics on a eukaryotic enzyme, sepiapterin reductase, causing alterations in neurotransmitter synthesis [79].

## 7. Conclusions and Perspectives

*o*-Benzoic sulfimide or saccharin has been known for over a century as a chemical compound and has been used in the food industry as a sugar substitute for more than half a century. Saccharin has passed the test of time, during which it became clear that concerns about its carcinogenicity and teratogenicity are exaggerated, as it is approved of by the Joint FAO/WHO Expert Committee on Food Additives

(JECFA) and the European Commission Scientific Committee on Food (CS/ADD/EDUL/148-FINAL February 1997) and is permitted for use in more than 90 countries.

Evidence indicates that the spectrum of properties of this substance is wide and includes antibacterial activity. Until recently, the mechanism of the antibacterial action of saccharin was not characterized, so this article attempted to systematize the available information on this topic and suggest a possible mechanism of the effect of *o*-benzoic sulfimide on the vital systems of bacterial cells.

There is a definite similarity between the mechanisms of the antibacterial action of saccharin and sulfa drugs, and the therapeutic target in both cases should be folic acid of the microbial cell. However, saccharin can only act as a prodrug. Undergoing biogenic transformation, it is able to transform into *o*-sulphamoylbenzoic acid, which is a structural and, apparently, functional analog of several groups of remedies called sulphonamides.

The growing emergence and spread of pathogens resistant to antimicrobial drugs, especially to their natural variants, are a growing concern. This reflects the relevance of the search for new antibacterial therapeutics with rare functional groups or with a non-natural core structure, since the resistance of microorganisms to these develops much more slowly [80–83]. New data on the antimicrobial action of *o*-benzoic sulfimide indicates the prospects of this compound as a basis for creating a whole group of new antibacterial isothiazolidine derivatives for the pharmaceutical, food, and agricultural industries.

**Author Contributions:** Conceptualization, D.V.G.; methodology, E.Y.K. and D.V.G.; data curation, E.Y.K.; writing, E.Y.K., and D.V.G.; English translation and final approval of the version to be published, E.Y.K. and D.V.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** The work was performed in the framework of the Program for Basic Research of Russian State Academies of Sciences for 2013–2020 (0518- 2018- 0001, Russia).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Warner, D.J. Ira Remsen, Saccharin, and the Linear Model. *Ambix* **2008**, *55*, 50–61. [[CrossRef](#)]
2. Bizzari, S.N.; Leder, A.; Ishikawa, Y. High-intensity sweeteners. In *Chemical Economics Handbook*; SRI International: Menlo Park, CA, USA, 1996; p. 82.
3. Bruno, S.N.; Cardoso, C.R.; Maciel, M.M.A.; Vokac, L.; Junior, A.I.D.S. Selective identification and quantification of saccharin by liquid chromatography and fluorescence detection. *Food Chem.* **2014**, *159*, 309–315. [[CrossRef](#)] [[PubMed](#)]
4. Position of the American Dietetic Association: Use of Nutritive and Nonnutritive Sweeteners. *J. Am. Diet. Assoc.* **2004**, *104*, 255–275. [[CrossRef](#)] [[PubMed](#)]
5. Tripathi, M.; Khanna, S.K.; Das, M. Usage of saccharin in food products and its intake by the population of Lucknow, India. *Food Addit. Contam.* **2007**, *23*, 1265–1275. [[CrossRef](#)] [[PubMed](#)]
6. Fahlberg, C. Manufacture of Saccharine Compounds. US Patent No. 10,667, 1 December 1885.
7. Roth, K.; Lück, E. Die Saccharin-Saga. *Chem. Unserer Zeit* **2011**, *45*, 406–423. [[CrossRef](#)]
8. Bryan, G.T.; Ertürk, E.; Yoshida, O. Production of Urinary Bladder Carcinomas in Mice by Sodium Saccharin. *Science (New York, N.Y.)* **1970**, *168*, 1238–1240. [[CrossRef](#)]
9. Whysner, J.; Williams, G.M. Saccharin mechanistic data and risk assessment: Urine composition, enhanced cell proliferation, and tumor promotion. *Pharmacol. Ther.* **1996**, *71*, 225–252. [[CrossRef](#)]
10. Bell, W.; Clapp, R.; Davis, D.; Epstein, S.; Farber, E.; Fox, D.A.; Holub, B.; Jacobson, M.F.; Lijinsky, W.; Millstone, E.; et al. Carcinogenicity of saccharin in laboratory animals and humans. *Int. J. Occup. Environ. Health.* **2002**, *8*, 387–393.
11. Turner, S.D.; Tinwell, H.; Piegorsch, W.; Schmezer, P.; Ashby, J. The male rat carcinogens limonene and sodium saccharin are not mutagenic to male Big Blue™ rats. *Mutagenesis* **2001**, *16*, 329–332. [[CrossRef](#)]
12. Gallus, S.; Scotti, L.; Negri, E.; Talamini, R.; Franceschi, S.; Montella, M.; Giacosa, A.; Maso, L.D.; La Vecchia, C. Artificial sweeteners and cancer risk in a network of case–control studies. *Ann. Oncol.* **2007**, *18*, 40–44. [[CrossRef](#)]

13. Myers, R.L. *The 100 Most Important Chemical Compounds: A Reference Guide*; Greenwood Press: Westport, Conn, 2007; Volume 1, p. 352.
14. Takayama, S.; Sieber, S.M.; Adamson, R.H.; Thorgeirsson, U.P.; Dalgard, D.W.; Arnold, L.L.; Cano, M.; Eklund, S.; Cohen, S.M. Long-term feeding of sodium saccharin to nonhuman primates: Implications for urinary tract cancer. *J. Natl. Cancer Inst.* **1998**, *90*, 19–25. [[CrossRef](#)] [[PubMed](#)]
15. Weihrauch, M.R.; Diehl, V. Artificial sweeteners-do they bear a carcinogenic risk? *Ann. Oncol.* **2004**, *15*, 1460–1465. [[CrossRef](#)] [[PubMed](#)]
16. Priebe, P.M.; Kauffman, G.B. Making governmental policy under conditions of scientific uncertainty: A century of controversy about saccharin in congress and the laboratory. *Minerva* **1980**, *18*, 556–574. [[CrossRef](#)]
17. Kessler, I.I. Saccharin, cyclamate, and human bladder cancer. No evidence of an association. *JAMA* **1978**, *240*, 349–355. [[CrossRef](#)] [[PubMed](#)]
18. U.S. Food and Drug Administration. Additional Information about High-Intensity Sweeteners Permitted for Use in Food in the United States. Available online: <https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397725.htm> (accessed on 19 December 2017).
19. Bian, X.; Tu, P.; Chi, L.; Gao, B.; Ru, H.; Lu, K. Saccharin induced liver inflammation in mice by altering the gut microbiota and its metabolic functions. *Food Chem. Toxicol.* **2017**, *107*, 530–539. [[CrossRef](#)] [[PubMed](#)]
20. Cury, J.A.; Rocha, E.P.; Koo, H.; Francisco, S.B.; Cury, A.A.D.B. Effect of saccharin on antibacterial activity of chlorhexidine gel. *Braz. Dent. J.* **2000**, *11*, 29–34.
21. Oldacay, M.; Erdem, G. The Effect of Sodium Saccharin on the Growth of Escherichia coli, Proteus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus aureus and Enterococcus faecalis. *Türk. Mikrobiyol. Cem. Derg.* **2000**, *30*, 35–37.
22. Hamama, W.S.; Zoorob, H.H.; Gouda, M.A.; Afsah, E.M. Synthesis and antimicrobial and antioxidant activities of simple saccharin derivatives with N-basic side chains. *Pharm. Chem. J.* **2011**, *45*, 118–124. [[CrossRef](#)]
23. Patil, R.B.; Nagaraj, T.; Patel, V.B.; Prashant, G.M. The Antimicrobial Activity of the Three Commercially Available Intense Sweeteners against Common Periodontal Pathogens: An in vitro Study. *J. Contemp. Dent. Pr.* **2012**, *13*, 749–752. [[CrossRef](#)]
24. Fayad, N.K.; Al-Noor, T.H.; Ghanim, F.H. Synthesis, Characterization, And Antibacterial Activities of Manganese (II), Cobalt(II), Iron (II), Nickel (II), zinc (II) And Cadmium(II) Mixed- Ligand Complexes Containing Amino Acid (L-Valine) and Saccharin. *Adv. Phys. Theor. Appl.* **2012**, *9*, 1–13.
25. Csakai, A.; Smith, C.; Davis, E.; Martinko, A.; Coulup, S.; Yin, H. Saccharin Derivatives as Inhibitors of Interferon-Mediated Inflammation. *J. Med. Chem.* **2014**, *57*, 5348–5355. [[CrossRef](#)] [[PubMed](#)]
26. El-Sabbagh, O.I. Synthesis of Some New Benzisothiazolone and Benzenesulfonamide Derivatives of Biological Interest Starting from Saccharin Sodium. *Arch. der Pharm.* **2013**, *346*, 733–742. [[CrossRef](#)] [[PubMed](#)]
27. Siddiqui, W.A.; Ahmad, S.; Siddiqui, H.L.; Tariq, M.I.; Parvez, M. O-Sulfamoylbenzoic acid. *Acta Cryst.* **2007**, *E 63*, o4117. [[CrossRef](#)]
28. Sünderhauf, A.; Pagel, R.; Kuenstner, A.; Wagner, A.E.; Rupp, J.; Ibrahim, S.; Derer, S.; Sina, C. Saccharin Supplementation Inhibits Bacterial Growth and Reduces Experimental Colitis in Mice. *Nutrients* **2020**, *12*, 1122. [[CrossRef](#)] [[PubMed](#)]
29. Wang, Q.-P.; Browman, D.; Herzog, H.; Neely, G.G. Non-nutritive sweeteners possess a bacteriostatic effect and alter gut microbiota in mice. *PLoS ONE* **2018**, *13*, e0199080. [[CrossRef](#)]
30. Radford, T.; Cook, J.; Dalsis, D.; Wolf, E.; Voigt, M. Characterization of aminosaccharins in commercial sodium saccharin produced by the Maumee process. *Food Chem. Toxicol.* **1985**, *23*, 419–428. [[CrossRef](#)]
31. Budavari, S.; O'Neil, M.; Smith, A.; Heckelman, P.; Obenchain, J. *The Merck Index, Print Version*, 12th ed.; Merck & Co: Rahway, NJ, USA, 1996; 1741p.
32. Mitchell, M.; Pearson, R. Saccharin. In *Alternative Sweeteners*; Gelardi, R., Ed.; Marcel Dekker: New York, NY, USA, 1991; pp. 127–156.
33. Lide, D.R. *CRC Handbook of Chemistry and Physics*, 78th ed.; CRC Press: Boca Raton, FL, USA, 1997; p. 66.
34. Barceloux, D.G. *Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals*; Wiley: Hoboken, NJ, USA, 2008; 1157p.



35. Fife, T.H.; Natarajan, R.; Shen, C.C.; Bemb, R. Mechanism of thiazolidine hydrolysis. Ring opening and hydrolysis of 1,3-thiazolidine derivatives of p-(dimethylamino)cinnamaldehyde. *J. Am. Chem. Soc.* **1991**, *113*, 3071–3079. [[CrossRef](#)]
36. Mukund, S.C. *Drug Discovery and Development*, 1st ed.; Drug Development; Wiley: Hoboken, NJ, USA, 2007; Volume 2, 400p.
37. Knight, P. Hydrolysis of p-NN'-phenylenebismaleimide and its adducts with cysteine. Implications for cross-linking of proteins. *Biochem. J.* **1979**, *179*, 191–197. [[CrossRef](#)]
38. Baldwin, J.E.; Schofield, C.J. The biosynthesis of  $\beta$ -lactams. In *The Chemistry of  $\beta$ -lactams*; Page, M.I., Ed.; Springer: Dordrecht, The Netherlands, 1992; pp. 1–78. [[CrossRef](#)]
39. Frau, J.; Coll, M.; Donoso, J.; Muñoz, F.; Vilanova, B.; Blanco, F.G. Alkaline and acidic hydrolysis of the  $\beta$ -lactam ring. *Electron. J. Theor. Chem.* **1997**, *2*, 56–65. [[CrossRef](#)]
40. Deshpande, A.D.; Baheti, K.G.; Chatterjee, N.R. Degradation of  $\beta$ -lactam antibiotics. *Curr. Sci.* **2004**, *87*, 1684–1695.
41. Jakka, S.R.; Muges, G. Effect of  $\beta$ -lactamase-catalyzed hydrolysis of cephalosporins on peroxynitrite-mediated nitration of serum albumin and cytochrome C. *Indian J. Chem.* **2011**, *50A*, 447–452.
42. Palomo, C.; Oiarbide, M.  $\beta$ -Lactam Ring Opening: A Useful Entry to Amino Acids and Relevant Nitrogen-Containing Compounds Heterocyclic Scaffolds. In *Topics in Heterocyclic Chemistry*; Banik, B.K., Ed.; Springer Science and Business Media LLC: Berlin/Heidelberg, Germany, 2010; pp. 211–259.
43. Korzekwa, K.; Trager, W.; Gouterman, M.; Spangler, D.; Loew, G. Cytochrome P450 mediated aromatic oxidation: A theoretical study. *J. Am. Chem. Soc.* **1985**, *107*, 4273–4279. [[CrossRef](#)]
44. Groutas, W.C.; Chong, L.S.; Venkataraman, R.; Epp, J.B.; Kuang, R.; Houser-Archield, N.; Hoidal, J.R. The Gabriel-Colman rearrangement in biological systems: Design, synthesis and biological evaluation of phthalimide and saccharin derivatives as potential mechanism-based inhibitors of human leukocyte elastase, cathepsin G and proteinase 3. *Bioorganic Med. Chem.* **1995**, *3*, 187–193. [[CrossRef](#)]
45. Ragnarsson, U.; Grehn, L. Novel Gabriel reagents. *Accounts Chem. Res.* **1991**, *24*, 285–289. [[CrossRef](#)]
46. Rydberg, P.; Ryde, U.; Olsen, L. Prediction of Activation Energies for Aromatic Oxidation by Cytochrome P450†. *J. Phys. Chem. A* **2008**, *112*, 13058–13065. [[CrossRef](#)]
47. Sahi, J.; Black, C.B.; Hamilton, G.A.; Zheng, X.; Jolley, S.; Rose, K.A.; Gilbert, D.; Lecluyse, E.L.; Sinz, M.W. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. *Drug Metab. Dispos.* **2003**, *31*, 439–446. [[CrossRef](#)]
48. Guengerich, F.P. Mechanisms of cytochrome P450 substrate oxidation: MiniReview. *J. Biochem. Mol. Toxicol.* **2007**, *21*, 163–168. [[CrossRef](#)]
49. Greule, A.; Stok, J.E.; De Voss, J.J.; Cryle, M.J. Unrivalled diversity: The many roles and reactions of bacterial cytochromes P450 in secondary metabolism. *Nat. Prod. Rep.* **2018**, *35*, 757–791. [[CrossRef](#)]
50. Zhang, X.; Peng, Y.; Zhao, J.; Li, Q.; Yu, X.; Acevedo-Rocha, C.G.; Li, A. Bacterial cytochrome P450-catalyzed regio- and stereoselective steroid hydroxylation enabled by directed evolution and rational design. *Bioresour. Bioprocess.* **2020**, *7*, 1–18. [[CrossRef](#)]
51. Ullrich, R.; Hofrichter, M. Enzymatic hydroxylation of aromatic compounds. *Cell. Mol. Life Sci.* **2007**, *64*, 271–293. [[CrossRef](#)]
52. Krest, C.M.; Onderko, E.L.; Yosca, T.H.; Calixto, J.C.; Karp, R.F.; Livada, J.; Rittle, J.; Green, M.T. Reactive Intermediates in Cytochrome P450 Catalysis. *J. Biol. Chem.* **2013**, *288*, 17074–17081. [[CrossRef](#)] [[PubMed](#)]
53. Guengerich, F.P. Mechanisms of Cytochrome P450-Catalyzed Oxidations. *ACS Catal.* **2018**, *8*, 10964–10976. [[CrossRef](#)] [[PubMed](#)]
54. Soldatenkov, A.T.; Kolyadina, N.M.; Shendrik, I.V. *Fundamentals organic chemistry medicinal substances (Osnovy organicheskoy khimii lekarstvennykh veshchestv)*, 2nd ed.; M:Mir: Moscow, Russia, 2003; 192p. (In Russian)
55. Ghorab, M.M.; Ismail, Z.H.; Radwan, A.A.; Abdalla, M. Synthesis and pharmacophore modeling of novel quinazolines bearing a biologically active sulfonamide moiety. *Acta Pharm.* **2013**, *63*, 1–18. [[CrossRef](#)] [[PubMed](#)]
56. Chen, J.; Zhou, X.; Zhang, Y.; Gao, H. Potential toxicity of sulfanilamide antibiotic: Binding of sulfamethazine to human serum albumin. *Sci. Total. Environ.* **2012**, *432*, 269–274. [[CrossRef](#)]
57. Bailey, L.B.; Gregory, J.F. Folate Metabolism and Requirements. *J. Nutr.* **1999**, *129*, 779–782. [[CrossRef](#)]

58. Orsi, R.O.; Fernandes, A., Jr.; Bankova, V.; Sforcin, J.M. Antibacterial effects of Brazilian and Bulgarian propolis and synergistic effects with antibiotics acting on the bacterial DNA and folic acid. *Nat. Prod. Res.* **2012**, *26*, 344–349. [[CrossRef](#)]
59. Marbois, B.; Xie, L.X.; Choi, S.; Hirano, K.; Hyman, K.; Clarke, C.F. para-Aminobenzoic Acid Is a Precursor in Coenzyme Q6 Biosynthesis in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **2010**, *285*, 27827–27838. [[CrossRef](#)]
60. Korolkovas, A. [Conformation and inter-atomic distances in the p-aminobenzoic acid and sulfanilamide]. *Rev. Paul. de Med.* **1973**, *82*, 185–192.
61. Korolkovas, A. [Conformations and interatomic distances in polymorphs of sulfanilamide]. *Rev. de Farm. e Bioquim. da Univ. de Sao Paulo* **1976**, *14*, 109–125.
62. Morland, J.; Olsen, H. Metabolism of sulfadimidine, sulfanilamide, p-aminobenzoic acid, and isoniazid in suspensions of parenchymal and nonparenchymal rat liver cells. *Drug Metab. Dispos.* **1977**, *5*, 511–517.
63. Roland, S.; Ferone, R.; Harvey, R.J.; Styles, V.L.; Morrison, R.W. The characteristics and significance of sulfonamides as substrates for *Escherichia coli* dihydropteroate synthase. *J. Biol. Chem.* **1979**, *254*, 10337–10345. [[PubMed](#)]
64. Brown, G.M. The biosynthesis of folic acid II. Inhibition by sulfonamides. *J. Biol. Chem.* **1962**, *237*, 536–540. [[PubMed](#)]
65. Swarbrick, J.; Iliades, P.; Simpson, J.S.; Macreadie, I.G. Folate Biosynthesis - Reappraisal of Old and Novel Targets in the Search for New Antimicrobials. *Enzym.* **2008**, *1*, 12–33. [[CrossRef](#)]
66. Levorato, C.; Mantovan, R. [On possible interference of p-aminobenzoic acid in the determination of folic acid]. *Boll. Chim. Farm.* **1966**, *105*, 231–236.
67. Zevzikoviene, A.; Zevzikovas, A.; Tarasevicius, E.; Pavlonis, A.; Dirse, V. Synthesis and in vitro antimicrobial study of 4-thiazolidinone containing sulfanilamide. *Acta Pol. Pharm.-Drug Res.* **2012**, *69*, 911–915.
68. Masadeh, M.M.; Mhaidat, N.M.; I Al-Azzam, S.; Alzoubi, K.H. Investigation of the antibacterial activity of pioglitazone. *Drug Des. Dev. Ther.* **2011**, *5*, 421–425. [[CrossRef](#)]
69. Nawale, S.L.; Dhake, A.S. Synthesis and evaluation of novel thiazolidinedione derivatives for antibacterial activity. *Der Pharma Chemica.* **2012**, *4*, 2270–2277.
70. Ward, F.; Coates, M.; Walker, R. Nitrate reduction, gastro-intestinal pH and N-nitrosation in gnotobiotic and conventional rats. *Food Chem. Toxicol.* **1986**, *24*, 17–22. [[CrossRef](#)]
71. Ward, F.W.; Coates, M.E. Gastrointestinal pH measurement in rats: Influence of the microbial flora, diet and fasting. *Lab. Anim.* **1987**, *21*, 216–222. [[CrossRef](#)]
72. Fallingborg, J. Intraluminal pH of the human gastrointestinal tract. *Dan. Med Bull.* **1999**, *46*, 183–196.
73. Barlow, M.; Hall, B.G. Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. *J. Mol. Evol.* **2002**, *55*, 314–321. [[CrossRef](#)] [[PubMed](#)]
74. Hall, B.G.; Barlow, M. Evolution of the serine beta-lactamases: Past, present and future. *Drug Resist Updat.* **2004**, *7*, 111–123. [[CrossRef](#)] [[PubMed](#)]
75. Bush, K. Past and Present Perspectives on  $\beta$ -Lactamases. *Antimicrob. Agents Chemother.* **2018**, *62*, 01076-18. [[CrossRef](#)]
76. D'Costa, V.M.; King, C.E.; Kalan, L.; Morar, M.; Sung, W.W.L.; Schwarz, C.; Froese, D.G.; Zazula, G.D.; Calmels, F.; Debruyne, R.; et al. Antibiotic resistance is ancient. *Nat. Cell Biol.* **2011**, *477*, 457–461. [[CrossRef](#)] [[PubMed](#)]
77. Kim, D.-W.; Thawng, C.N.; Lee, K.; Wellington, E.M.; Cha, C.-J. A novel sulfonamide resistance mechanism by two-component flavin-dependent monooxygenase system in sulfonamide-degrading actinobacteria. *Environ. Int.* **2019**, *127*, 206–215. [[CrossRef](#)] [[PubMed](#)]
78. Sousa, F.L.; Martin, W.F. Biochemical fossils of the ancient transition from geoenergetics to bioenergetics in prokaryotic one carbon compound metabolism. *Biochim. et Biophys. Acta (BBA) Bioenerg.* **2014**, *1837*, 964–981. [[CrossRef](#)] [[PubMed](#)]
79. Bourne, C.R. Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery. *Antibiotics* **2014**, *3*, 1–28. [[CrossRef](#)] [[PubMed](#)]
80. Boyle-Vavra, S.; Daum, R.S. Community-acquired methicillin-resistant *Staphylococcus aureus*: The role of Pantone-Valentine leukocidin. *Lab. Investig.* **2007**, *87*, 3–9. [[CrossRef](#)]
81. Tishkov, V.; Savin, S.; Yasnaya, A. Protein Engineering of Penicillin Acylase. *Acta Naturae* **2010**, *2*, 47–61. [[CrossRef](#)]

82. Wright, G.D. Antibiotic resistance in the environment: A link to the clinic? *Curr. Opin. Microbiol.* **2010**, *13*, 589–594. [[CrossRef](#)]
83. Gajdács, M. The Concept of an Ideal Antibiotic: Implications for Drug Design. *Molecules* **2019**, *24*, 892. [[CrossRef](#)] [[PubMed](#)]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).